- Home
- SAGE vs OABI Comparison
SAGE vs OABI Comparison
Compare SAGE & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- OABI
- Stock Information
- Founded
- SAGE 2010
- OABI 2012
- Country
- SAGE United States
- OABI United States
- Employees
- SAGE N/A
- OABI N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- SAGE Health Care
- OABI Health Care
- Exchange
- SAGE Nasdaq
- OABI Nasdaq
- Market Cap
- SAGE 462.2M
- OABI 388.5M
- IPO Year
- SAGE 2014
- OABI N/A
- Fundamental
- Price
- SAGE $6.94
- OABI $3.22
- Analyst Decision
- SAGE Hold
- OABI Strong Buy
- Analyst Count
- SAGE 20
- OABI 4
- Target Price
- SAGE $11.39
- OABI $9.00
- AVG Volume (30 Days)
- SAGE 2.8M
- OABI 448.8K
- Earning Date
- SAGE 02-12-2025
- OABI 11-12-2024
- Dividend Yield
- SAGE N/A
- OABI N/A
- EPS Growth
- SAGE N/A
- OABI N/A
- EPS
- SAGE N/A
- OABI N/A
- Revenue
- SAGE $106,399,000.00
- OABI $20,409,000.00
- Revenue This Year
- SAGE N/A
- OABI N/A
- Revenue Next Year
- SAGE $122.32
- OABI $78.61
- P/E Ratio
- SAGE N/A
- OABI N/A
- Revenue Growth
- SAGE 837.60
- OABI N/A
- 52 Week Low
- SAGE $4.62
- OABI $3.16
- 52 Week High
- SAGE $27.68
- OABI $6.55
- Technical
- Relative Strength Index (RSI)
- SAGE 60.28
- OABI 32.70
- Support Level
- SAGE $6.75
- OABI $3.16
- Resistance Level
- SAGE $7.88
- OABI $3.29
- Average True Range (ATR)
- SAGE 0.38
- OABI 0.13
- MACD
- SAGE 0.13
- OABI -0.02
- Stochastic Oscillator
- SAGE 64.39
- OABI 9.09
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.